ArticleFrontiers in neurology2025
Propofol-related biological alterations and incidence of propofol infusion syndrome in status epilepticus: a 10-year cohort study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Continuation of sedative infusions during palliative extubation for refractory status epilepticus in hepatic encephalopathy: A case report.SAGE open medical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Continuous anesthetics are often required for the management of refractory status epilepticus. While essential to achieving seizure control, these agents carry significant adverse effects. In particular, propofol may induce hypotension, respiratory depression, metabolic acidosis, or pancreatitis, with the most feared complication being propofol infusion syndrome (PRIS). Methods: The primary objective was to investigate the biological effects of propofol in patients with status epilepticus admitted to the neurointensive care unit of Pitié-Salpêtrière Hospital (Paris, France) for at least 48 h between September 2015 and October 2024. Twenty biological parameters reflecting acid-base balance, organ function, lipid metabolism, and inflammation were analyzed. To capture delayed effects, biological tests from day Results: A total of 235 patients were enrolled, of whom 51% received propofol for at least 1 day. We collected biological data over 2,407 patient-days, including 1,086 (45%) under propofol infusion. Propofol use was associated with lipid dysregulation, characterized by increased triglycerides, decreased LDL-cholesterol and HDL-cholesterol, along with impaired renal function, and mild acute respiratory acidosis, reflected by elevated pCO Discussion: Prolonged propofol infusions warrant routine monitoring of specific biological markers. Our study identifies key parameters to follow and confirms that PRIS remains rare in specialized centers where patients are closely monitored and risk factors are carefully considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.